-
San Diego Biotech Deal Brings Up to $100M Per Target to Peptide Drug Discovery
Aizen has secured a partnership potentially worth up to $100 million per target, fueling further research and development into peptide-based therapeutics.
-
FDA Eases Restrictions on Six Peptides, Expanding Access for Researchers and Consumers
The FDA has relaxed restrictions on six peptide compounds, potentially broadening access for research and compounding use. Here’s what the change means for the peptide community.
-
FDA Advisory Panel Gives Green Light to Six Peptides for Compounding
An FDA expert panel has voiced support for allowing six specific peptides to be compounded, a step that could expand patient access to these therapies through licensed compounding pharmacies.
-
Arch Biopartners to Expand LSALT Peptide Trial into the United States
Arch Biopartners is broadening the clinical trial footprint of its LSALT peptide into the US, a sign of growing momentum behind the investigational therapy. The expansion could accelerate patient enrollment and data collection.
-
New Clinical Trial Explores How Leucine Dosing Could Help Preserve Muscle During Fasting-Based Weight Loss
A newly registered study will examine whether different doses of the amino acid leucine can help young men maintain muscle mass while following a four-week alternate-day fasting program.
-
New Clinical Trial Aims to Improve Diabetes and Celiac Disease Screening for Underserved Communities
A newly launched study, ACCESS-T1D, seeks to improve early detection of Type 1 diabetes and celiac disease among underserved children and adults, expanding access to screening and care.
-
New Clinical Trial Explores BOTOX for Masseter Muscle Prominence
A new study is investigating whether BOTOX injections can safely and effectively reduce masseter muscle prominence, a common cosmetic concern related to lower facial width. The trial aims to expand treatment options for adults seeking a less invasive solution.
-
Pfizer’s Berobenatide Shows Promise in Phase IIb Trial
Pfizer has announced encouraging Phase IIb results for berobenatide, an investigational peptide therapy, marking another step forward in peptide-based treatment research.
-
GV1001 Peptide Shows Promise Against Alzheimer’s Disease in Mouse Study
A peptide derived from human telomerase, known as GV1001, has been shown in a new study to reverse signs of neurodegeneration in a mouse model of Alzheimer’s disease. The findings offer an encouraging new avenue for future therapeutic development.
-
Arch Biopartners Set to Expand LSALT Peptide Clinical Trial into the United States
Arch Biopartners is broadening its clinical trial program for its investigational LSALT peptide into the US, a sign of growing momentum behind the therapy’s development. The expansion could speed enrollment and bring the treatment closer to patients who may benefit.